H + -ATPase, a multisubunit protein found in virtually every cell type which is essential for vesicle trafficking, protein degradation, and coupled transport. Nevertheless, selective (P)RR blockade in the brain with the putative antagonist PRO20 (corresponding with the first 20 amino acids of prorenin's prosegment) reduced blood pressure in the deoxycorticosteroneacetate (DOCA)-salt model, and (P)RR gene single nucleotide polymorphisms associate with hypertension. To what degree this relates to (pro)renin remains uncertain. The concept of (P)RR blockade in hypertension, if pursued, requires rigorous testing of any newly designed antagonist, and may not hold promise given the early death of tissue-specific (P)RR knockout animals.
Tissue angiotensin (Ang) II levels greatly exceed the angiotensin levels in plasma, [1] [2] [3] [4] [5] and it is therefore generally assumed that tissues are the predominant site of angiotensin generation. This coincides with the observation that the beneficial effects of renin-angiotensin system (RAS) blockers in multiple organs are independent, at least in part, of the blood pressure-lowering effect of these drugs: they reflect interference with tissue angiotensin generation/action.
Although it has been hotly debated for years whether tissue angiotensin generation occurs intracellularly, e.g., in cardiomyocytes, convincing evidence for this concept is lacking. In heart, brain, and adrenal, a renin transcript lacking exon 1, encoding for a non-secretory intracellular renin, [6] [7] [8] has been demonstrated. Yet, to what degree this renin variant displays activity, and if so, in what intracellular compartment it reacts with angiotensinogen (to generate Ang I), is still unknown. Moreover, subsequent intracellular cleavage by Ang I-converting enzyme would then also be required, and evidence for such intracellular Ang I-converting enzyme activity is lacking. Xu et al. generated mice in which secreted (i.e., wild-type) renin was replaced by intracellular renin. 7 They observed that these animals exhibited the same renal lesions, inability to generate concentrated urine, decreased arterial pressure, and impaired aortic constriction as renin-null mutants lacking the entire renin gene. 7 Clearly therefore, intracellular renin was unable to replace the actions of secreted renin, i.e., it did not result in angiotensin generation. Moreover, studies in Ang II type 1 (AT 1 ) receptor) knockout mice revealed that, in the absence of AT 1 receptors, there was no intracellular angiotensin. 9 Thus, intracellular Ang II represents Ang II that has entered the cell via AT 1 receptor-mediated internalization, 10 and is not derived from intracellularly acting renin. This implies that tissue angiotensin generation occurs exclusively extracellular, either in interstitial fluid or on the cell surface.
A second controversial issue is where the renin and angiotensinogen that act locally are coming from. Originally, it was thought that these components were also synthesized at tissue sites, as opposed to the hepatic origin of circulating angiotensinogen and the renal origin of circulating renin. Obviously, this would greatly increase the complexity of the RAS, since then its regulation would be different in each organ. For instance, in support of this concept, mast cells have been proposed as a potential source of renin in the heart. 11 However, several other studies did not support independent cardiac synthesis of renin. Renin activity disappears not only entirely from plasma after a bilateral nephrectomy, 12, 13 but also from cardiac tissue. 14, 15 The isolated perfused rat Langendorff heart does not release renin, 16, 17 not even following a myocardial infarction, when the number of mast cells in the heart has greatly increased. 18 Moreover, the cardiac tissue levels of renin closely correlate with the plasma levels of renin, both under normal and pathological
The Role of the (Pro)renin Receptor in Hypertensive Disease A.H. Jan Danser 1 Tissue angiotensin generation depends on the uptake of circulating (kidney-derived) renin and/or its precursor prorenin (together denoted as (pro)renin). Since tissue renin levels are usually higher than expected based upon the amount of (renin-containing) blood in tissue, an active uptake mechanism has been proposed. The (pro)renin receptor ((P) RR), discovered in 2002, appeared a promising candidate, although its nanomolar affinity for renin/prorenin is many orders of magnitude above their levels in blood. This review discusses (P)RR-related research since its discovery. First, encouraging in vitro findings supported detrimental effects of (pro)renin-(P)RR interaction, even resulting in angiotensin-independent signaling. Moreover, the putative (P)RR blocker "handle region peptide" (HRP) yielded beneficial effects in various cardiovascular animal models. Then doubt arose whether such interaction truly occurs in vivo, and (P)RR deletion unexpectedly turned out to be lethal. Moreover, HRP results could not be confirmed. Finally, it was discovered that the (P)RR actually is a component of vacuolar-type conditions, 4, 14, 19 and cultured neonatal and adult rat cardiac myocytes and fibroblasts do not release renin into the medium. 20, 21 Comparable observations were made with regard to vascular renin. 22 Clearly therefore, the current belief is that renin in the body is entirely kidney-derived. This is not the case for prorenin, the inactive precursor of renin. After a nephrectomy, prorenin levels decrease, but then stabilize. 12 This is due to prorenin synthesis at extrarenal sites, like the adrenal gland, testes, ovaries, placenta, and eyes, 23 in addition to constitutive prorenin release from the kidneys. The function of prorenin is unclear, particularly at these extrarenal sites, given the fact that outside the kidney there is no evidence for its conversion to renin. Remarkably, despite its apparent lack of function, prorenin levels in humans are ≈10-fold higher than those of renin.
With regard to angiotensinogen, emphasis on its local (extrahepatic) synthesis has been on the kidney, where angiotensinogen mRNA occurs in the proximal straight tubule. 24 Yet, elegant studies applying selective knockout of renal angiotensinogen revealed that the concept of renal angiotensinogen contributing to renal Ang II production is not true: all renal Ang II generation depended on hepatic angiotensinogen, both under normal and pathological conditions. 25, 26 Similar conclusions have been reached in the heart. 16 Indeed, cardiac tissue levels of angiotensinogen corresponded with 10-20% of the levels in plasma, compatible with the concept that its levels in interstitial fluid resemble those in blood plasma (note that blood and interstitial fluid together make up 10-20% of tissue weight). This implies that angiotensinogen in plasma (which is liver-derived) diffuses into the interstitial space, to allow local (extracellular) angiotensin production. Studies in a modified version of the isolated perfused rat Langendorff heart, allowing separate collection of coronary effluent and interstitital transudate, confirmed the diffusion of both renin and angiotensinogen into the cardiac interstitial space. 16 However, the renin levels in cardiac tissue, when expressed per gram tissue, are often as high as those in plasma, if not higher, and some of this renin appeared to be membrane-associated. 14, 27 This implies that renin is not limited to extracellular fluid. Moreover, isolated perfused hearts of rats transgenic for human angiotensinogen released Ang I during renin infusion and this release continued after stopping the renin infusion. 28 Similarly, the disappearance of tissue renin after a bilateral nephrectomy occurred more slowly than that of plasma renin. 14, 29 Taken together, these data are suggestive for the concept that circulating renin binds to a renin-binding protein/receptor, and that bound renin is catalytically active. Even more interesting might be if such receptors would also bind prorenin, particularly if this would result in prorenin activation.
WHAT RECEPTOR MEDIATES TISSUE (PRO)RENIN ACCUMULATION?
The search for a renin receptor has been ongoing for decades since the above-mentioned observations. An intracellular renin-binding protein was described first. This turned out to be identical to the enzyme N-acyl-d-glucosamine 2-epimerase. 30 Confusingly, it inhibited renin in vitro, and mice lacking this protein did not display any major alteration in their circulating or renal RAS. 30 Clearly, this excluded a role for this protein as a contributor to tissue RAS activity. Next, the mannose 6-phosphate/insulin-like growth factor II receptor was investigated extensively. Such receptors cycle constitutively among the Golgi, endosomes, and the plasma membrane, and the majority is located in a late endosomal/prelysosomal compartment. Extracellular lysosomal enzymes that bind to cell surface mannose 6-phosphate/insulin-like growth factor II receptors are internalized via clathrin-coated pits. They dissociate from the receptor in acidified endosomal compartments and are subsequently delivered to lysosomes. The receptor is then reutilized. Since a large percentage of plasma renin and prorenin is phosphomannosylated, both proteins bind to this receptor with high affinity (K d ≈ 1 nmol/l). Such binding was found to be followed by internalization in a variety of cells, including cardiomyocytes, fibroblasts, vascular smooth muscle cells, and endothelial cells. [31] [32] [33] [34] [35] [36] Moreover, prorenin was converted to renin by an as yet unidentified enzyme after internalization. 33 Thus, this receptor seemed to fulfill the ideal for a renin receptor: it bound not only renin, but also prorenin, and the latter even resulted in prorenin activation, albeit intracellularly. However, evidence for a functional role (i.e., Ang I generation) of this internalized renin and prorenin could not be obtained-at most, internalization resulted in the intracellular degradation of renin, presumably in lysosomes, and prorenin-renin conversion turned out to be the first step toward degradation of prorenin. 32, 33, 35 Therefore, the mannose 6-phosphate/insulin-like growth factor II receptor is a clearance receptor for renin/prorenin, and does not facilitate local RAS activity.
Then, in 2002, an entirely new receptor was described, which bound both renin and prorenin, and which was suggested to have no other functions. 37 It was immediately named "(pro)renin receptor" or (P)RR. Interestingly, (P)RR binding of prorenin appeared to induce a conformational change in the molecule, by which the prosegment is moved out of the catalytic cleft and the active site became exposed, leading to full activation of prorenin ( Figure 1 ). Yet, such activation was not accompanied by actual cleavage of the prosegment, so that it is known as "non-proteolytic" activation, to distinguish it from the proteolytic activation of prorenin (involving actual prosegment removal) in the kidney. Here it should be noted that non-proteolytic activation of prorenin is a well-known phenomenon, with the active, open conformation occurring particularly at low temperature and low pH. 38 In fact, under physiological conditions (37 °C, pH = 7.4), a small percentage (<2%) of prorenin in blood plasma displays the active conformation. As such, it will be recognized in renin-specific assays, thereby potentially resulting in an overestimation of renin levels. 39 The (P)RR is a 350 amino acid-, ubiquitously expressed transmembrane protein that binds (pro)renin to a large N-terminal extracellular domain ( Figure 2 ). 37 Binding studies in rat vascular muscle cells that overexpress the human (P)RR revealed that prorenin binds with higher affinity (K d ≈ 5 nmol/l), suggesting that prorenin might be the endogenous ligand for the (P)RR. 40 The (pro)renin-binding domain is followed by a carboxyterminal half that is comprised of Figure 1 . Proposed functions of the (P)RR in prorenin activation and signaling, as well as its relationship to V-ATPase and Wnt signaling. Binding of Wnt to Frizzled/low-density lipoprotein receptor-related protein 5/6 (Fz/LRP5/6) complex results in stabilization of β-catenin, which then translocates to the nucleus where it complexes with the T-cell factor/lymphocyte enhancer binding factor (TCF/LEF) to induce the expression of Wnt target genes. Wnt/β-catenin signaling requires the internalization of the Fz/LRP5/6 complex and subsequent acidification of the signaling endosomes by V-ATPases. Acidification of the endosomes requires the presence of the (P)RR, which acts as a physical adaptor between the Fz/LRP6 complex and the V-ATPase. Abbreviations: ACE, angiotensin I-converting enzyme; Ang, angiotensin; MAPK, mitogen-activated protein kinase; Erk1/2, extracellular-signal-regulated kinase 1/2; Hsp27, Heat-shock protein 27; PAI-1, plasminogen-activator inhibitor-1; TGF-β 1 , transforming growth factor-β 1 ; COX, cyclo-oxygenase. Danser the rest of the extracellular domain, a single transmembrane domain, and a short intracellular tail that can form dimers. 41 The carboxyterminal part is conserved amongst all metazoans. 42 Importantly, this part was previously purified from chromaffin granules as an 8.9 kD accessory protein (M8-9) of the vacuolar-type H + -ATPase and designated ATP6AP2 (ATPase, H + -transporting, lysosomal accessory protein 2). 43 This suggests that the (P)RR can be proteolytically processed. Indeed, Cousin et al. 44 found a 28 kD soluble form of the (P)RR (s(P)RR), in the conditioned medium of several cell types. Both the serine protease furin and the metalloprotease ADAM19 have been proposed as (P)RR-cleaving proteases. 45 The availability of kits to quantify s(P)RR allowed its detection in plasma and urine. 46, 47 Disappointingly, its circulating levels were unrelated to the levels of either renin or prorenin. 47 An exciting possibility would be that prorenin binds to the sPRR and then displays activity in plasma. It can be calculated that, given the s(P)RR levels in the circulation (≈25 ng/ml or 1 nmol/l), at a K d of 5 nmol/l, around 20% of prorenin should display activity due to such binding. As discussed above, in reality <2% displays activity, and this percentage is virtually the same in buffer (i.e., in the absence of s(P)RR). Thus, currently, there is no evidence supporting prorenin activation in plasma through binding to the s(P) RR; possibly therefore, s(P)RR's affinity for prorenin is far below the 5 nmol/l range. Yet, in vitro studies do support prorenin binding to the cell-associated (P)RR. 40 Even more surprising was the observation that prorenin, as well as renin, induced signaling via this receptor, entirely independent from the formation of Ang I (Figure 1) . 37, 49 Indeed, binding of (pro)renin to the (P)RR activated the mitogen-activated protein kinase extracellular-signal-related kinase 1/2 (Erk1/2) in several cell types, including mesangial cells, 37, 50 collecting duct cells, 51 vascular smooth muscle cells, 49, 52, 53 monocytes, 42 and neurons. 54 Activation of Erk1/2 increased cell proliferation and stimulated production of transforming growth factor β1, resulting in the upregulation of profibrotic factors, such as plasminogen-activated inhibitor-1, fibronectin and collagen. 50, 55, 56 Erk1/2 activation is also linked to V-ATPase activity, as prorenin-induced Erk1/2 phosphorylation in Madin-Darby Canine Kidney cells, a model for collecting duct cells, is inhibited by the V-ATPase inhibitor bafilomycin A1. 51, 57 Furthermore, prorenin binding activated the serine/threonine kinase Akt in vascular smooth muscle cells 53 and the p38 mitogen-activated protein kinase-Heat-shock protein 27 cascade in cardiomyocytes, which regulates actin cytoskeleton dynamics. 58 
THE GOLDEN AGE OF THE (P)RR RESEARCH
At the time the (P)RR was discovered, renin inhibitors were being developed. The existence of such a receptor, possibly mediating angiotensin-independent effects, was a clear threat to such drugs, since the use of renin inhibitors would (via interference with the negative feedback loop) result in high levels of renin and prorenin, which could then possibly induce side effects via (P)RR stimulation. Unfortunately, but perhaps not too surprising, renin inhibition did not block (P)RR-induced signaling. 42, 49 Thus, interest rose to investigate this phenomenon in detail. Conveniently, Suzuki et al. designed a peptidic antagonist based on the idea that the prosegment of prorenin contains a "handle region" (10P-19P) that binds to the receptor, allowing prorenin to become catalytically active. 59 A peptide mimicking the handle region ("handle region peptide" or HRP) would thus bind competitively to the receptor, thereby preventing receptor-mediated prorenin activation (so that tissue RAS activity would decrease) and prorenin-induced signaling. Because prorenin is highly species-specific, different HRPs exist for humans, rats, and mice.
Initially, all evidence pointed to detrimental consequences of prorenin-(P)RR interaction and beneficial effects of HRP. Rodents overexpressing prorenin developed renal and cardiac pathology in a blood pressure-independent manner, 60 ubiquitous overexpression of the human (P)RR in rats resulted in proteinuria and glomerulosclerosis (Table 1) , 61, 62 and rats that overexpressed the human (P)RR in smooth muscle cells displayed hypertension (Table 1) . 63 HRP prevented the development of glomerulosclerosis in human (P) RR transgenic rats, and yielded additional beneficial effects in various pathological models: it prevented/regressed diabetic nephropathy, ocular inflammation, retinopathy, cardiac hypertrophy, and fibrosis, as reviewed elsewhere. 64 Since these effects also occurred in AT 1 receptor-deficient animals, 65 it was concluded that they largely represented blockade of the angiotensin-independent effects of renin and prorenin. This may explain why blood pressure-lowering effects were never observed during HRP treatment. Interest from industry arose to develop a non-peptidic (P)RR antagonist that might be applied in a variety of diseases, particularly those that are accompanied by high prorenin levels, like diabetes.
DOUBT ARISES: DOES PRORENIN-(P)RR INTERACTION TRULY OCCUR IN VIVO AND CAN HRP PREVENT THIS?
Immediately after the beneficial effects of HRP had been published, its use became more widespread. Remarkably, all this work was done without a rigorous assessment of the (P) RR-antagonizing properties of HRP, e.g., in classical binding assays. Therefore, until today we do not know how well HRP blocks (pro)renin binding. Quite a few papers were unable to demonstrate blockade of (pro)renin-induced signaling when applying micromolar concentrations of HRP. 42, 49 Some even suggested that HRP is a (partial) (P)RR agonist, 57, 74 while others demonstrated HRP binding to cells not expressing the (P)RR. 42 Subsequent in vivo studies observed no or detrimental effects of HRP (including a rise in blood pressure) in a variety of hypertension and diabetes models. [74] [75] [76] [77] [78] [79] Moreover, in new transgenic models increased expression of the (P)RR had no effect in the heart or kidney, nor affected blood pressure. 66, 67 Even more worrying was the fact that the prorenin concentrations required to stimulate the receptor were in the nanomolar range. This is not surprising given the observed K d value (5 nmol/l), but difficult to reconcile with the prorenin levels in vivo (5 pmol/ml). 80 For renin, these differences are even more striking: it binds with at least 4-fold reduced affinity (K d ≈ 20 nmol/l) and its in vivo levels in humans are in the order of 0.5 pmol/l. Consequently, assuming that stimulation requires levels that are ≈10-fold above K d , for prorenin levels 10,000 times its normal levels in plasma are needed and for renin even levels 400,000 times its normal levels. Such rises do not normally occur. A 100-fold rise in renin is feasible, e.g., in Bartter's syndrome, patients with renal artery stenosis, or after RAS inhibition. For prorenin, increases are usually much more modest, e.g., 2-to 3-fold in patients with diabetes. 81 Even the excessive prorenin-renin levels present in transgenic models are still far below the required range. Therefore, until now, such high concentrations could only be applied in vitro, due to availability of recombinant human renin and prorenin in microgram amounts. To what degree such results have physiological relevance remains uncertain. One might speculate that perhaps in renal interstitial fluid 400,000-fold higher renin levels exist, while in prorenin-synthesizing organs the interstitial prorenin levels might be several orders of magnitude above those in plasma. Alternatively, an unknown facilitating mechanism might exist in vivo, which allows renin and prorenin to exert effects via their receptor at much lower levels. Currently, evidence for both options is lacking.
A reevaluation of the original transgenic rat model displaying severe blood pressure-independent renal and cardiac pathology after prorenin overexpression, 60 did not confirm this phenotype, 82 nor did comparable transgenic models reveal blood pressure-independent effects (like fibrosis and glomerulosclerosis) of prorenin. 83, 84 In fact, the rise in blood pressure after prorenin overexpression fully normalized in the presence of RAS inhibition, 83 indicating that the hypertension was simply Ang II-dependent. Here one should keep in mind that, under physiological conditions, a small percentage of prorenin will display activity due to non-proteolytic activation, as discussed above. Obviously therefore, when increasing plasma prorenin several hundred-fold, 84 this might already considerably increase angiotensin generation in the absence of any receptor.
Finally, (P)RR −/− mice were reported to be lethal at a very early stage. 85 Since this is not the case for renin knockout mice, these data unequivocally imply that the (P)RR has vital functions beyond the RAS. Summarizing, the findings obtained with HRP are not uniform, (pro)renin-(P)RR interaction requires pharmacological (pro)renin 73 CAG, CMV early enhancer/chicken β-actin; CD, collecting duct; COX, cyclo-oxygenase; Crx, cone-rod homeobox; Hoxb7, homeobox protein Hox-B7; HR, heart rate; MHC, myosin heavy chain; n.a., not available; PGE 2 , prostaglandin E2; SBP, systolic blood pressure; SM, smooth muscle.
concentrations, and prorenin transgenic animals display an Ang II-dependent phenotype. Together with the lethal consequences of (P)RR deletion, this raises doubt whether (pro) renin-(P)RR interaction occurs in normal physiology.
THE TRUTH ABOUT THE (P)RR?
Since (P)RR −/− mice do not survive, 85 the focus to unravel the (patho)physiological role of the (P)RR shifted to the generation of tissue-specific knockouts (Table 1) . These studies indicated an essential role for the (P)RR in V-ATPase integrity. V-ATPases are multisubunit proteins that consist of a V 0 proton-translocation domain, a V 1 pump domain, and 2 associated proteins, Ac45 and the (P)RR (Figure 2 ). V-ATPases are found in virtually all cell types, mostly on the membranes of intracellular compartments, and are important for vesicle trafficking, protein degradation, and coupled transport. 48 In some cell types, V-ATPases are also abundantly present at the plasma membrane, for example, in intercalated cells of the collecting duct, where they regulate systemic acid-base homeostasis. 86 Cardiomyocyte-specific ablation of the (P)RR resulted in a lethal phenotype, with newborn mice dying within 3 weeks of heart failure. 68 Similarly, podocyte-specific (P)RR knockout mice were born at Mendelian rates, but early in life developed nephritic syndrome, with severe proteinuria and albuminuria due to progressive glomerular sclerosis, and they died within 2-4 weeks of renal failure. 70, 71, 87 The podocytes of these mice showed massive foot-process effacements accompanied by alterations in the actin cytoskeleton, whereas the slit diaphragm proteins, nephrin, and podocin had reduced expression and were redistributed to the cytosol. 70, 71 (P)RR-depleted cardiomyocytes and podocytes were both highly vacuolarized and showed impaired autophagic degradation. The autophagy defect was due to deacidification of intracellular vesicles, which is caused by the selective down-regulation of V 0 subunits. 68, 71 These findings suggest that the (P)RR is essential for the assembly, stability, and function of V-ATPase. Indeed, insertional mutagenesis of the (P)RR gene in zebrafish and injection of morpholino RNAs against the (P)RR into cleavage-staged Xenopus embryos gave very similar developmental phenotypes, identical to the phenotypes found for V-ATPase subunits mutants. [88] [89] [90] Furthermore, specific (P)RR knockout in vascular smooth muscle cells, 69 photoreceptor cells, 72 and the ureteric bud 73 also resulted in phenotypes associated with disturbed V-ATPase function (Table 1) .
In 2010, the (P)RR gene was identified in human embryonic kidney cells in an siRNA library screen designed to find previously unknown components of the canonical Wnt/β-catenin signaling pathway. 89 The canonical Wnt/β-catenin signaling pathway is important for embryonic development and tissue homeostasis, and has been implicated in certain pathologies, such as cancer and diabetes. Wnt/β-catenin signaling is critically dependent on the acidification of signaling endosomes by V-ATPases, hence the indispensable role of the (P)RR (Figure 1 ). Similar observations were made for the Wnt/Planar Cell Polarity (Wnt/PCP) pathway, which among others determines the orientation of wing hairs in Drosophila. 91, 92 Since the latter do not possess a RAS, this confirms that the (P)RR also functions independently from (pro)renin.
The link with Wnt/β-catenin signaling might underlie the phenotype of (P)RR-overexpressing rats, as well as some of the effects induced by prorenin when bound to the (P)RR (Figure 1) . Indeed, Wnt/β-catenin signaling is increased in podocytes and glomeruli of diabetic patients and rodents, 93 and acts downstream of transforming growth factor β1 to induce the expression of profibrotic markers, including plasminogen-activated inhibitor-1. 94, 95 A unifying concept might therefore be that (P)RR overexpression/deletion has functional consequences, related to V-ATPase activation, and that HRP somehow interferes with (P)RR/V-ATPase, be it as an agonist or antagonist. Although this would explain most (P)RR-related data obtained so far, it does not imply that (pro)renin-(P)RR interaction by definition occurs in vivo.
(P)RR BLOCKADE: DOES IT HAVE A FUTURE IN HYPERTENSION?
Genome-wide association studies have identified several single nucleotide polymorphisms in the (P)RR gene that are associated with increased cardiovascular risk. In a Japanese cohort, the intervening sequence (IVS)5+169C>T polymorphism was significantly and independently related to ambulatory blood pressure. 96 The significant higher ambulatory blood pressure for T-allele carriers was confirmed in Caucasian men. 97 Also 2 polymorphisms, 1 in the promoter region and 1 in an intron of the (P)RR gene, were significantly associated with hypertension in 2 vascular disease populations of coronary artery disease (EUROPA) and cerebrovascular disease (PROGRESS). 98 Furthermore, a unique exonic splice enhancer mutation that results in a partly truncated form of the receptor (Δ4-(P)RR) was found in a family with X-linked mental retardation and epilepsy. 99 No display of cardiovascular or renal abnormalities was reported in the carriers of this mutation. These findings point toward the brain as an important site of (P)RR expression. In fact, the (P)RR is widely expressed in the human brain, 100 with the highest expression found in the pituitary and front lobe. It co-localized with vasopressin and oxytocin in the paraventricular and supraoptic nuclei, raising the possibility that the (P)RR is related to the central control of water-electrolyte metabolism and/or blood pressure. Indeed, adeno-associated virus-mediated overexpression of the human (P)RR in the supraoptic nucleus of normal rats resulted in increases in plasma and urinary vasopressin, and decreases in water intake and urine output, without any effect on blood pressure or heart rate. 101 Vice versa, knockdown in the supraoptic nucleus of spontaneously hypertensive rats attenuated the age-dependent increases in blood pressure and decreased heart rate and plasma vasopressin. 101 Yet, the same authors reported that (P)RR knockdown in the nucleus of the solitary tract of the spontaneously hypertensive rats induced blood pressure elevation in an Ang II-independent manner. 102 Thus, confusingly, in the supraoptic nucleus the (P)RR is prohypertensive (possibly via stimulation of angiotensin formation), 101 whereas in the nucleus of the solitary tract it is antihypertensive.
In support of the former, neuron-specific (P)RR knockout prevented deoxycorticosteroneacetate (DOCA)-salt-induced hypertension. 103 Activation of the brain RAS is believed to be essential for the increased sympathetic activity and development of hypertension in the DOCA-salt model. Indeed, DOCA-salt increased brain Ang II ≈5-fold in wild-type mice, but not in neuron-specific (P)RR knockout mice. Yet, DOCA-salt did not increase brain renin/prorenin levels. 103 In fact, these levels, when measured by enzyme-kinetic assay (≈60 ng Ang I/g per hour), corresponded with around 2% of the plasma levels of (pro)renin in mice (≈3000 ng Ang I/g per hour). 104 Thus, as is widely accepted, brain (pro)renin levels are excessively low, and the presence of <5% blood in brain tissue may already be enough to entirely explain the presence of (pro)renin in the brain. This leaves the question how brain Ang II has increased 5-fold in the DOCA-salt model.
In a subsequent study in the DOCA-salt model, Li et al. infused a newly designed putative (P)RR antagonist, PRO20 (corresponding with the first 20 amino acids of the prosegment of mouse prorenin), into the brain and observed this to reduce blood pressure to the same degree as losartan. 105 This was attributed to a reduction of the Ang II levels in the cortex and hypothalamus. Yet, since this reduction was only ≈25%, brain Ang II levels were still elevated 3-to 4-fold above wild-type levels when blood pressure had normalized. Even more surprising was that intracerebroventricular infusion of PRO20 also lowered blood pressure in transgenic mice expressing human renin and angiotensinogen, despite the fact that these mice displayed hypertension due to a 4-fold elevation of plasma Ang II. Thus, either the hypertension in this transgenic model is not due to the activation of the circulating RAS, or PRO20 acts outside the brain, e.g., as a renin inhibitor. Li et al. also performed binding studies in mouse brain tissue with PRO20 fluorescently labeled at the N-terminus with fluorescein isothiocyanate (PRO20-FITC). 105 Fluorescence in mouse brain tissue increased concentration-dependently, and 1 µmol/l mouse prorenin fully prevented fluorescence accumulation during tissue exposure to 5 nmol/l PRO20-FITC. Confusingly, when repeating these studies in human brain tissue, concentration-dependent fluorescence accumulation was again observed (despite the species difference between humans and mice, both with regard to renin and the (P)RR) and now 1 µmol/l human prorenin (1 million times the normal levels of prorenin in human plasma!) prevented such accumulation.
Taken together, these findings are reminiscent of the early observations on HRP over a decade ago. It is too early to conclude that PRO20 is the long-awaited (P)RR antagonist that blocks prorenin-(P)RR-dependent Ang II formation. The brain is the organ with the lowest (pro)renin levels in the body, in which only the nonfunctional intracellular renin variant is expressed locally. Prorenin-(P)RR interaction, like renin-angiotensinogen interaction, is species-dependent. Thus, mouse PRO20-FITC accumulating equally well in mouse and human brain tissue is difficult to understand, let alone the fact that one needs prorenin at levels 1 millionfold above normal to prevent such accumulation. Like with HRP, we need rigorous binding studies with PRO20, as well as convincing evidence that brain (pro)renin levels are high enough to allow interaction with the (P)RR, before jumping into in vivo studies with this new compound. Of course, the concept that the brain (P)RR contributes to (neurogenic) hypertension is exciting, but this may well occur via its link with V-ATPase and Wnt/β-catenin signaling (i.e., independently of prorenin). Moreover, given the antihypertensive role of the (P)RR in the nucleus of the solitary tract, 102 achieving blockade at the right brain site will be a challenge.
CONCLUSION
Over a decade of RAS-oriented (P)RR research has resulted in a lot of confusion. Promising initial results could not be confirmed, and the (P)RR turned out to have completely different functions outside the RAS. Most likely, its true in vivo role concerns its contribution to V-ATPase integrity. As such it may well be involved in the signaling pathways of multiple receptors, potentially contributing to a variety of cardiovascular diseases including (neurogenic) hypertension. (Pro)renin levels in vivo are many orders of magnitude below the levels required to stimulate the (P) RR, and even transgenic animals models with excessively high prorenin levels did not display direct (i.e., Ang II/ blood pressure-independent) effects of prorenin. Whether the prorenin levels required to stimulate the (P)RR exist in prorenin-synthesizing organs remains unknown. The (P) RR antagonists that have been proposed until now (HRP, PRO20) have never undergone rigorous testing, making it impossible to conclude whether their actions have anything to do with (P)RR blockade and/or prorenin. Moreover, both pro-and antihypertensive effects of (P)RR stimulation have been reported in the brain. 101, 102 Combined with the lethal consequences of (P)RR deletion in heart and kidney this rather seems to argue against the therapeutic application of (P)RR antagonists in hypertension.
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